CGCharles E. Gaber

Charles E. Gaber

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles E. Gaber has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A retrospective cohort study on the comparative safety of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on the onset of gallbladder disease in type II diabetes

    by Katie Carlson, Jasmeen Kaur, Charles E. Gaber, Sirimon Reutrakul, Kibum Kim

    Approximately 15.8% of the adult US population is estimated to have diabetes, with 90-95% of these cases representing Type II diabetes (T2D) with the national burden expected to continue rising in ...

  • Chemotherapy and Supportive Care Practice Patterns Among Older Adults With Metastatic Pancreatic Cancer

    by Charles E. Gaber, Abdullah I. Abdelaziz, Ida R. Johannsen, Jakob Kirkegård, Todd A. Lee, Aaron N. Winn, Ryan D. Nipp

    PURPOSE: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a leading cause of cancer mortality in the United States. Although fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine with NAB-paclitaxel (GnP) represent first-line chemotherapy options for mPDAC, practice patterns in older adults remain understudied. We describe national treatment trends, factors associated with treatment selection, and receipt of second-line treatment in older adults with mPDAC. METHODS: Using the SEER-Medicare linked database (2010-2019), we identified a cohort of individuals age 66 years and older diagnosed with mPDAC who initiated infusion chemotherapy within 90 days of diagnosis. Temporal trends in first-line treatment selection were quantified for the overall population and stratified by levels of a claims-based frailty index (robust, prefrail, and frail). We used multinomial logistic regression to describe associations between patient factors and first-line agent received adjusted for year of diagnosis. We characterized median time on first-line therapy, use of supportive care interventions, and receipt of second-line therapy. RESULTS: Among 7,473 adults with mPDAC (median age = 74 years, 50.7% female), gemcitabine monotherapy was the predominant treatment in 2010 at 69.3%, but in 2019 it fell to the third most-used regimen (16.6%) behind GnP (45.2%) and FOLFIRINOX (20.9%). In the most recent data (2019), 29.8%, 19.8%, and 6.8% of robust, prefrail, and frail individuals received FOLFIRINOX, respectively. Factors associated with regimen selection included age, sex, race/ethnicity, comorbidity, and frailty. Approximately one third of FOLFIRINOX initiators received second-line GnP (36.3%) and vice versa (31.1%). CONCLUSION: Chemotherapy use has evolved for older adults with mPDAC and varies across levels of baseline frailty. The heterogeneity in chemotherapy selection and practice patterns in older adults merits ongoing investigation to help ensure patients receive treatment tailored to their unique geriatric needs.


  • Open Access

    Cardiovascular Risks of Aromatase Inhibitors versus Tamoxifen in Postmenopausal Breast Cancer: A Multinational Cohort Study

    by Shu-Chen Hu, Charles Gaber, Chiao Lo, Hsuanyun Neo Su, Chi-Chuan Wang, Chih-Fan Yeh, Lubna Hassan, A Simon Pickard, Todd Lee, Fang-Ju Lin

    Background: Aromatase inhibitors (AIs) are the preferred treatment for postmenopausal women with hormone receptor-positive (HR+) breast cancer, but their cardiovascular safety remains uncertain. This study compared cardiovascular risks associated with AIs versus tamoxifen in two distinct populations. Patients and methods: This retrospective cohort study used data from the US SEER-Medicare database (2007– 2020) and Taiwan’s National Health Insurance claims database and cancer registry (2010– 2021). Postmenopausal women with HR+ stage I–III breast cancer were categorized by their initial endocrine therapy. Study outcomes included major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and heart failure (HF). Covariate balance was achieved through inverse probability of treatment weighting, and cause-specific hazard models were used for risk assessment in each cohort. Results: The study included 36,950 US patients (89% AI users) and 22,676 Taiwan patients (71% AI users). In the US, AIs were associated with an HR of 1.13 (95% CI 0.83– 1.52) for MACE and 1.17 (95% CI 0.93– 1.48) for HF, compared to tamoxifen. In Taiwan, the HRs were 1.23 (95% CI 0.87– 1.73) for MACE and 0.93 (95% CI 0.73– 1.21) for HF. AI use was linked to a lower VTE risk in the US (HR: 0.35, 95% CI 0.27– 0.45), while the Taiwan cohort showed a non-significant trend (HR: 0.72, 95% CI 0.42– 1.25). Conclusion: AIs were not associated with a definitive increase in MACE or HF risk compared with tamoxifen, although confidence intervals suggest some uncertainty in the estimates. The observed differences in VTE risk across cohorts highlight the need for population-specific considerations when selecting endocrine therapy.


  • Open Access

    Treatment patterns of symptomatic treatments for Alzheimer’s disease and related dementias

    by Huiwen Deng, Todd A. Lee, Charles E. Gaber, Kibum Kim, Stephanie Y. Crawford, Elizabeth A. Bayliss, Sonal Singh, Jessica G. Young, Sengwee Toh, Xiaojuan Li

    Limited real-world evidence exists on the patterns of symptomatic treatment use for Alzheimer’s disease and related dementias (ADRD). Using data from


  • Association of opioid and benzodiazepine coprescribing with adverse events among older adults with cancer

    by Devon K Check, Samir Soneji, Harvey Jay Cohen, Andrea Des Marais, Katie F Jones, Charles E Gaber, Jessica S Merlin, Amy O’rEgan, Nicole Fergestrom, Lauren E Wilson, et al.

    Background: Many older adults with cancer are coprescribed opioids/benzodiazepines; evidence on harms is lacking. Methods: Using SEER-Medicare (2012-2019), we identified patients with breast, colorectal, or lung cancer. Cox proportional hazards models estimated the adjusted hazard ratios (HRs) of coprescribing (measured from claims, at the day level) with the immediate risk of overdose, fall/fracture, and all-cause hospitalization. In a secondary analysis, models were stratified by ≥90 days of continuous medication supply. Results: In our cohort of 107 288 patients, compared with those prescribed neither medication, those prescribed benzodiazepines had an increase in the immediate risk of falls/fractures (HR = 1.17, 95% CI = 1.02 to 1.34) and all-cause hospitalizations (HR = 1.08, 95% CI = 1.04 to 1.12). Patients prescribed opioids had an increase in the immediate risk of overdose (HR = 5.62, 95% CI = 4.86 to 5.62), falls/fractures (HR = 1.56, 95% CI = 1.41 to 1.73), and all-cause hospitalizations (HR = 1.26, 95% CI = 1.23 to 1.30). HRs were similar for patients coprescribed opioids/benzodiazepines. For patients without continuous exposure to 1 or both medications, effects were larger for coprescribed opioids/benzodiazepines vs opioids for overdose (HR = 15.22, 95% CI = 8.79 to 26.35 vs HR = 6.85, 95% CI = 6.85 to 26.35) and all-cause hospitalization (HR = 3.21, 95% CI = 2.60 to 3.96 vs HR = 1.98, 95% CI = 1.87 to 2.10). Conclusions: Overall, compared with no prescribing, benzodiazepine prescribing and opioid prescribing were each associated with an increase in the immediate risk of adverse events. Effects were similar for those prescribed opioids and those coprescribed opioids/benzodiazepines. For patients with intermittent vs long-term medication exposure, coprescribing additionally increased the risk of overdose and all-cause hospitalization.


  • Open Access

    Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer

    by Charles E. Gaber, Ebere Okpara, Abdullah I. Abdelaziz, Jyotirmoy Sarker, Kent A. Hanson, Lubna Hassan, Fang-Ju Lin, Todd A. Lee, Natalie M. Reizine


  • Open Access

    De‐Mystifying the Clone‐Censor‐Weight Method for Causal Research Using Observational Data: A Primer for Cancer Researchers

    by Charles E. Gaber, Armen A. Ghazarian, Paula D. Strassle, Tatiane B. Ribeiro, Maribel Salas, Camille Maringe, Xabier Garcia‐Albeniz, Richard Wyss, Wei Du, Jennifer L. Lund

    Background: Regulators and oncology healthcare providers are increasingly interested in using observational studies of real‐world data (RWD) to complement clinical evidence from randomized controlled trials for informed decision‐making. To generate valid evidence, RWD studies must be carefully designed to avoid systematic biases. The clone‐censor‐weight (CCW) method has been proposed to address immortal time and other time‐related biases.Methods: The objective of this manuscript is to de‐mystify the CCW method for cancer researchers by describing and presenting its core components in an accessible and digestible format, using visualizations and examples from cancer‐relevant studies. The CCW method has been applied in diverse settings, including investigations of the effects of surgery within a certain time after cancer diagnosis, the continuation of annual screening mammography, and chemotherapy duration on survival.Results: The method handles complex data wherein the treatment group to which an individual belongs is unknown at the start of follow‐up. The three steps of the CCW method involve cloning or duplicating the patient population and assigning one clone to each treatment strategy, artificially censoring the clones when their observed data are inconsistent with the assigned strategy and weighting the cloned and censored population to address selection bias created by the artificial censoring.Conclusions: The CCW method is a powerful tool for designing RWD studies in cancer that are free from time‐related biases and successfully, to the extent possible, emulate features of a randomized clinical trial.


  • The Clone-Censor-Weight Method in Pharmacoepidemiologic Research: Foundations and Methodological Implementation

    by Charles E. Gaber, Kent A. Hanson, Sodam Kim, Jennifer L. Lund, Todd A. Lee, Eleanor J. Murray


  • Open Access

    Adherence to prescription proton pump inhibitor therapy amongst individuals diagnosed with Barrett's esophagus

    by Charles E. Gaber, Abdullah I. Abdelaziz, Jyotirmoy Sarker, Jennifer L. Lund, Evan S. Dellon, Cary C. Cotton, Swathi Eluri, Nicholas J. Shaheen

    Introduction: In the United States, clinical guidelines recommend daily use of proton pump inhibitors (PPIs) amongst individuals diagnosed with Barrett's esophagus to decrease the risk of progression to dysplasia and neoplasia. Prior studies documenting adherence to PPIs in this population have not characterized heterogeneity in adherence patterns. Factors that may relate to adherence are incompletely described.Methods: We used administrative claims data from the Merative MarketScan Commercial Claims and Encounters database to conduct a retrospective study of adherence to prescription PPIs. A cohort of individuals diagnosed with incident Barrett's esophagus between 2010 and 2019 was identified. Group‐based trajectory models were generated to detect longitudinal adherence subgroups.Results: 79 701 individuals with a new diagnosis of Barrett's esophagus were identified. The best fitting model detected five distinct adherence trajectory groups: consistently high (44% of the population), moderate decline (18%), slow decline (12%), rapid decline (10%), and decline‐then‐increase (16%). Compared to individuals starting PPIs, those already using PPIs were less likely to have a declining adherence pattern. Other factors associated with membership in a declining adherence group included (but were not limited to): female sex, having a past diagnosis of anxiety or depression, and having one or more emergency department visits in the past year.Discussion: Using an exploratory method, we detected heterogeneity in adherence to prescription PPIs. Less than half of individuals were classified into the consistently high adherence group, suggesting that many individuals with Barrett's esophagus receive inadequate pharmacologic therapy.


  • Top Cited Papers
    Open Access

    Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta‐analysis

    by Charles E. Gaber, Jyotirmoy Sarker, Abdullah I. Abdelaziz, Ebere Okpara, Todd A. Lee, Samuel J. Klempner, Ryan D. Nipp

    Background: Neoadjuvant chemoradiation and chemotherapy are recommended for the treatment of nonmetastatic esophageal cancer. The benefit of neoadjuvant treatment is mostly limited to patients who exhibit pathologic complete response (pCR). Existing estimates of pCR rates among patients receiving neoadjuvant therapy have not been synthesized and lack precision.Methods: We conducted an independently funded systematic review and meta‐analysis (PROSPERO CRD42023397402) of pCR rates among patients diagnosed with esophageal cancer treated with neoadjuvant chemo(radiation). Studies were identified from Medline, EMBASE, and CENTRAL database searches. Eligible studies included trials published from 1992 to 2022 that focused on nonmetastatic esophageal cancer, including the gastroesophageal junction. Histology‐specific pooled pCR prevalence was determined using the Freeman–Tukey transformation and a random effects model.Results: After eligibility assessment, 84 studies with 6451 patients were included. The pooled prevalence of pCR after neoadjuvant chemotherapy in squamous cell carcinomas was 9% (95% CI: 6%–14%), ranging from 0% to 32%. The pooled prevalence of pCR after neoadjuvant chemoradiation in squamous cell carcinomas was 32% (95% CI: 26%–39%), ranging from 8% to 66%. For adenocarcinoma, the pooled prevalence of pCR was 6% (95% CI: 1%–12%) after neoadjuvant chemotherapy, and 22% (18%–26%) after neoadjuvant chemoradiation.Conclusions: Under one‐third of patients with esophageal cancer who receive neoadjuvant chemo(radiation) experience pCR. Patients diagnosed with squamous cell carcinomas had higher rates of pCR than those with adenocarcinomas. As pCR represents an increasingly utilized endpoint in neoadjuvant trials, these estimates of pooled pCR rates may serve as an important benchmark for future trial design.